The Fierce Innovation Awards: Life Sciences Edition have come to a close and we’re pleased to announce the 2020 award winners! These awards are designed to showcase organizations that over the past 12 months have demonstrated innovative technologies and services that have the potential to make the greatest impact for biotech and pharma companies. With…
New post hoc data from Phase III ASCLEPIOS trials showed newly diagnosed, treatment-naïve patients experienced reductions in annualized relapse rates, MRI lesion activity and reductions in time to disability worsening when treated with Kesimpta vs teriflunomide(1) Additional safety data in over 1,800 patients who continued Kesimpta treatment or switched therapy from previous studies reinforce the…
Responding to President Trump’s call to develop 300 million doses of SARS-CoV-2 vaccine by January under Operation Warp Speed, the U.S. Department of Health and Human Services (HHS) and AstraZeneca are collaborating to make available at least 300 million doses of a coronavirus vaccine called AZD1222, with the first doses delivered as early as October…
ZURICH (Reuters) – Swiss drugmaker Novartis said on Saturday that its investigational spartalizumab immuno-oncology drug mixed with the approved medicines Tafinlar and Mekinist failed in a late-stage trial for a type of advanced skin cancer. The drug did not improve progression-free survival in previously untreated patients with BRAF V600 mutation-positive cutaneous melanoma, compared to Tafinlar…
Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab. Patients with high cholesterol from a rare genetic disorder struggle to keep their cholesterol levels in check, despite taking multiple lipid-busting drugs. A new drug from Regeneron may change…
Operation Warp Speed, the federal government’s multi-agency push to develop a COVID-19 vaccine, is promising to provide 300 million doses by January 2021. That means funding for several of the top candidates. Moderna, one of the leaders of the pack, is already in Phase III trials after creating its first vaccine in a record-breaking 42…
An international team of researchers led by an Israeli scientist has developed a noninvasive technology to kill breast cancer cells, an innovation that in the future could perhaps also be used to treat diseases such as brain cancer, Alzheimer’s and Parkinson’s. The groundbreaking technique, developed by Tel Aviv University’s Tali Ilovitsh during her post-doctorate period…
LAVAL, QC, Aug. 6, 2020 /PRNewswire/ — Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”) today announced that it intends to spin off its leading eye health business into an independent publicly traded entity (“Bausch + Lomb – NewCo”) from the remainder of Bausch Health (“BHC”). The spinoff will establish two separate…
FLORHAM PARK, N.J., Aug. 5, 2020 /PRNewswire/ — Celularity today announced that it has been awarded a $750,000 COVID-19 Project grant by the California Institute for Regenerative Medicine (CIRM), one of the three clinical awards targeting the coronavirus. This grant will support California Institutions participating in the Phase I/II clinical trial of human placental hematopoietic stem cell derived natural killer (NK)…
On the heels of Pfizer’s $1.95 billion COVID-19 vaccine deal with the U.S. government, one analyst says the drugmaker could earn many more billions in revenue on its potential vaccine—if the program succeeds. At $1.95 billion for 100 million doses, Pfizer’s deal sets a price-per-dose of $19.50, which Bloomberg Intelligence analyst Sam Fazeli sees as…
